Veeva Systems (VEEV) closed the most recent trading day at $158.27, moving 4.06% from the previous trading session.

Veeva Systems (VEEV) is rated Buy, trading at multi-year lows despite robust 16% revenue growth, 44% non-GAAP margins, and conservative FY27 guidance. AI disruption fears are overstated for VEEV's FDA-regulated Development Cloud, which comprises 55% of revenue and remains highly defensible due to regulatory switching costs. Vault CRM migration is progressing, reducing Salesforce dependency and enhancing control over product roadmap and AI integration; CRM competition is real but not existential.

The latest trading day saw Veeva Systems (VEEV) settling at $164.96, representing a +1.01% change from its previous close.

VEEV benefits from RTSM traction with major pharma wins, strengthening its clinical software strategy and long-term R&D growth outlook.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.

Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector's short history, and bargain hunters are circling the wreckage.

VEEV expands Vault CRM adoption and AI capabilities with Roche and BioMarin partnerships as life sciences firms modernize workflows.

argenx, Bayer, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novo Nordisk, Takeda, and Vertex share how they are redefining engagement across sales, marketing, and medical PLEASANTON, Calif., May 14, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will showcase the future of agentic commercial in biopharma at Veeva Commercial Summit, May 19-20 in Boston.